PROKLAR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Proklar, and when can generic versions of Proklar launch?
Proklar is a drug marketed by Forest Pharms and is included in one NDA.
The generic ingredient in PROKLAR is sulfamethizole. There are four drug master file entries for this compound. Additional details are available on the sulfamethizole profile page.
Summary for PROKLAR
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 94 |
Patent Applications: | 4,576 |
Formulation / Manufacturing: | see details |
DailyMed Link: | PROKLAR at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for PROKLAR
US Patents and Regulatory Information for PROKLAR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Forest Pharms | PROKLAR | sulfamethizole | TABLET;ORAL | 080273-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |